With the big cancer confab ASCO 2016 fading into memory, R&D teams everywhere are getting back to work on their cancer programs – and across the industry many of them will be doing the same work, on the same targets, supporting the exploding supernova known as immuno-oncology.
{iframe}http://medcitynews.com/2016/06/immuno-oncology-rd-race/?utm_source=MedCity+News+Subscribers&utm_campaign=2b937cc038-MCN+Daily+Email&utm_medium=email&utm_term=0_5092836c41-2b937cc038-408826397{/iframe}